Medtox Scientific Inc. Board of Directors Under Investigation for Potential Breaches of Fiduciary Duty by Glancy Binkow & Gol...
04 Junio 2012 - 12:12PM
Business Wire
Glancy Binkow & Goldberg LLP announces that it is
investigating potential claims against the Board of Directors of
Medtox Scientific Inc. (“Medtox” or the “Company”) (NASDAQ: MTOX)
related to the proposed acquisition of the Company by Laboratory
Corp. of America. The transaction is valued at approximately $241
million.
This investigation concerns whether the Board of Directors of
Medtox breached their fiduciary duties to stockholders by failing
to adequately shop the Company before agreeing to enter into the
proposed transaction, and whether the Company has disclosed all
material information to shareholders about the transaction. The
Company has seen substantial recent growth. Its share price has
skyrocketed from $12.02 on September 22, 2011 to $22.10 on April
30, 2012.
If you are a shareholder of Medtox, if you have information or
would like to learn more about our investigation, or if you wish to
discuss these matters or have any questions concerning this
announcement or your rights or interests with respect to these
matters, please contact Louis Boyarsky, Esquire, Glancy Binkow
& Goldberg LLP, 1925 Century Park East, Suite 2100, Los
Angeles, CA 90067, by telephone at (310) 201-9150 or Toll Free at
(888) 773-9224 or by email to shareholders@glancylaw.com.
This press release may be considered Attorney Advertising in
some jurisdictions under the applicable law and ethical rules.
Medtox Scientific, Inc. (MM) (NASDAQ:MTOX)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Medtox Scientific, Inc. (MM) (NASDAQ:MTOX)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024
Real-Time news about Medtox Scientific, Inc. (MM) (NASDAQ): 0 recent articles
Más de Glancy Binkow & Goldberg LLP Artículos de Noticias